Every year I ask Dr. Scarlett if there is evidence with the observed disease modification, if some statement can be made regarding the progression of MDS and the transformation to AML can be made. Every year he says there is not enough data. Fair enough. But this year we see an exciting new abstract from Dr. Wen Ma. Dr. Ma's studies can only be described as elegant. Here is this years submission to ASH:
https://ash.confex.com/ash/2020/webprog ... 40771.html
Note also the last author, Dr. Catriona Jamieson and the ties to Forty Seven and CRIM.
Regards to all, bp
My favorite abstract
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
- Posts: 1669
- Joined: Fri Jul 20, 2018 5:13 pm
Re: My favorite abstract
Another potential combo?
About dasatinib from Wikipedia:
“ Dasatinib was developed by collaboration of Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd,[13][14][15] and named for Bristol-Myers Squibb research fellow Jagabandhu Das, whose program leader says that the drug would not have come into existence had he not challenged some of the medicinal chemists' underlying assumptions at a time when progress in the development of the molecule had stalled.[16]”
About dasatinib from Wikipedia:
“ Dasatinib was developed by collaboration of Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd,[13][14][15] and named for Bristol-Myers Squibb research fellow Jagabandhu Das, whose program leader says that the drug would not have come into existence had he not challenged some of the medicinal chemists' underlying assumptions at a time when progress in the development of the molecule had stalled.[16]”
Re: My favorite abstract
They are saying disease modification a lot at the ER! Right? Thanks.
-
- Posts: 1669
- Joined: Fri Jul 20, 2018 5:13 pm
Re: My favorite abstract
Right. A lot. A whole lot. The potential to change the entire natural history of these diseases is apparent. Including impacting the evolution to AML.